- Home
- COOT vs SYBX Comparison
COOT vs SYBX Comparison
Compare COOT & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOT
- SYBX
- Stock Information
- Founded
- COOT 2020
- SYBX N/A
- Country
- COOT Australia
- SYBX United States
- Employees
- COOT N/A
- SYBX 6
- Industry
- COOT
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- COOT
- SYBX Health Care
- Exchange
- COOT NYSE
- SYBX Nasdaq
- Market Cap
- COOT 20.4M
- SYBX 15.9M
- IPO Year
- COOT N/A
- SYBX N/A
- Fundamental
- Price
- COOT $0.92
- SYBX $1.36
- Analyst Decision
- COOT
- SYBX Buy
- Analyst Count
- COOT 0
- SYBX 4
- Target Price
- COOT N/A
- SYBX $15.50
- AVG Volume (30 Days)
- COOT 144.8K
- SYBX 11.7K
- Earning Date
- COOT 01-01-0001
- SYBX 11-12-2024
- Dividend Yield
- COOT N/A
- SYBX N/A
- EPS Growth
- COOT N/A
- SYBX N/A
- EPS
- COOT N/A
- SYBX N/A
- Revenue
- COOT N/A
- SYBX $2,777,000.00
- Revenue This Year
- COOT N/A
- SYBX N/A
- Revenue Next Year
- COOT N/A
- SYBX N/A
- P/E Ratio
- COOT N/A
- SYBX N/A
- Revenue Growth
- COOT N/A
- SYBX 292.23
- 52 Week Low
- COOT $0.61
- SYBX $1.22
- 52 Week High
- COOT $11.96
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- COOT 60.88
- SYBX 40.49
- Support Level
- COOT $0.61
- SYBX $1.37
- Resistance Level
- COOT $0.77
- SYBX $1.58
- Average True Range (ATR)
- COOT 0.10
- SYBX 0.09
- MACD
- COOT 0.02
- SYBX -0.00
- Stochastic Oscillator
- COOT 96.83
- SYBX 0.00
About COOT AUSTRALIAN OILSEEDS HOLDINGS LTD
Australian Oilseeds Holdings Ltd through its subsidiaries, is focused on the manufacture and sale of chemical-free, non-GMO, sustainable edible oils and products derived from oilseeds. The company believes that transitioning from a fossil fuel economy to a renewable and chemical-free economy is the solution to many health problems the world is facing presently.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.